Session » Abstracts: Muscle Biology, Myositis & Myopathies – Basic & Clinical Science II

Date: Wednesday, November 15, 2023

Time: 9:00AM-10:30AM

Meeting: ACR Convergence 2023

9:00AM-10:30AM: Abstract Number: 2575

Accurate Stratification of Cancer Risk in a Real-World Cohort Using the International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening

9:00AM-10:30AM: Abstract Number: 2577

Frequency of Atherosclerotic Cardiovascular Disease Following a Diagnosis of Idiopathic Inflammatory Myopathy: Data from a Large National Registry

9:00AM-10:30AM: Abstract Number: 2580

High-intensity Resistance Training Improves Quality of Life, Muscle Endurance and Strength in Patients with Myositis

9:00AM-10:30AM: Abstract Number: 2578

Machine Learning Identifies New Sporadic Inclusion Body Myositis Endotypes Associated with Unique Autoantibody Profiles

9:00AM-10:30AM: Abstract Number: 2576

Rapid Onset of Response in Adult Dermatomyositis Patients Receiving Anti-interferon β (PF-06823859): Results of a Phase 2, Double-blind, Randomized, Placebo-Controlled Study

9:00AM-10:30AM: Abstract Number: 2579

Validation of PROMIS in Adult and Pediatric Patients with Idiopathic Inflammatory Myopathies

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].